The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Open accessAbstract
BACKGROUND: occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population. METHODS: exon 14 skipping mutation was detected on liquid biopsy or tissue biopsy. RESULTS: As of January 1, 2020, a total of 152 patients had received tepotinib, and 99 patients had been followed for at least 9 months. The response rate by independent review was 46% (95% confidence interval [CI], 36 to 57), with a median duration of response of 11.1 months (95% CI, 7.2 to could not be estimated) in the combined-biopsy group. The response rate was 48% (95% CI, 36 to 61) among 66 patients in the liquid-biopsy group and 50% (95% CI, 37 to 63) among 60 patients in the tissue-biopsy group; 27 patients had positive results according to both methods. The investigator-assessed response rate was 56% (95% CI, 45 to 66) and was similar regardless of the previous therapy received for advanced or metastatic disease. Adverse events of grade 3 or higher that were considered by investigators to be related to tepotinib therapy were reported in 28% of the patients, including peripheral edema in 7%. Adverse events led to permanent discontinuation of tepotinib in 11% of the patients. A molecular response, as measured in circulating free DNA, was observed in 67% of the patients with matched liquid-biopsy samples at baseline and during treatment. CONCLUSIONS: exon 14 skipping mutation, the use of tepotinib was associated with a partial response in approximately half the patients. Peripheral edema was the main toxic effect of grade 3 or higher. (Funded by Merck [Darmstadt, Germany]; VISION ClinicalTrials.gov number, NCT02864992.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Self-citationAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617
Self-citationAlectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A. B., Mezquita, L., Thai, A. A., Mascaux, C., Couraud, S., Veillon, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz167 · Cited by 1,354
Self-citationMerker, J. D., Oxnard, G. R., Compton, C., Diehn, M., Hurley, P., Lazar, A. J., Lindeman, N., Lockwood, C. M., Rai, A. J., Schilsky, R. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.8671 · Cited by 959
Frampton, G. M., Ali, S. M., Rosenzweig, M., Chmielecki, J., Lu, X., Bauer, T. M., Akimov, M., Bufill, J. A., Lee, C., Jentz, D., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0285 · Cited by 796
Awad, M. M., Oxnard, G. R., Jackman, D. M., Savukoski, D. O., Hall, D., Shivdasani, P., Heng, J. C., Dahlberg, S. E., Jänne, P. A., Verma, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4600 · Cited by 693
Paik, P. K., Drilon, A., Fan, P.-D., Yu, H., Rekhtman, N., Ginsberg, M. S., Borsu, L., Schultz, N., Berger, M. F., Rudin, C. M., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1467 · Cited by 575
Self-citationTong, J. H., Yeung, S. F., Chan, A. W. H., Chung, L. Y., Chau, S. L., Lung, R. W. M., Tong, C. Y., Chow, C., Tin, E. K. Y., Yu, Y. H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2061 · Cited by 449
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Drilon, A., Clark, J. W., Weiss, J., Ou, S.-H. I., Camidge, D. R., Solomon, B. J., Otterson, G. A., Villaruz, L. C., Riely, G. J., Heist, R. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0716-8 · Cited by 395
Self-citationCharacterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations
Schrock, A. B., Frampton, G. M., Suh, J., Chalmers, Z. R., Rosenzweig, M., Erlich, R. L., Halmos, B., Goldman, J., Forde, P., Leuenberger, K., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.004 · Cited by 384
Sabari, J. K., Leonardi, G. C., Shu, C. A., Umeton, R., Montecalvo, J., Ni, A., Chen, R., Dienstag, J., Mrad, C., Bergagnini, I., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy334 · Cited by 320
Self-citationWu, Y.-L., Cheng, Y., Zhou, J., Lu, S., Zhang, Y., Zhao, J., Kim, D.-W., Soo, R. A., Kim, S.-W., Pan, H., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30154-5 · Cited by 258
Self-citationHovelson, D. H., McDaniel, A. S., Cani, A. K., Johnson, B., Rhodes, K., Williams, P. D., Bandla, S., Bien, G., Choppa, P., Hyland, F., et al. (2015) · Neoplasia · doi:10.1016/j.neo.2015.03.004 · Cited by 224
Recondo, G., Bahcall, M., Spurr, L. F., Che, J., Ricciuti, B., Leonardi, G. C., Lo, Y.-C., Li, Y. Y., Lamberti, G., Nguyen, T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3608 · Cited by 220
Qi, J., McTigue, M. A., Rogers, A., Lifshits, E., Christensen, J. G., Jänne, P. A., & Engelman, J. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1623 · Cited by 216
Fujino, T., Kobayashi, Y., Suda, K., Koga, T., Nishino, M., Ohara, S., Chiba, M., Shimoji, M., Tomizawa, K., Takemoto, T., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.06.023 · Cited by 177
Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer
Bahcall, M., Sim, T., Paweletz, C. P., Patel, J. D., Alden, R. S., Kuang, Y., Sacher, A. G., Kim, N. D., Lydon, C. A., Awad, M. M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0686 · Cited by 173
Self-citationAcquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping
Heist, R. S., Sequist, L. V., Borger, D., Gainor, J. F., Arellano, R. S., Le, L. P., Dias-Santagata, D., Clark, J. W., Engelman, J. A., Shaw, A. T., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.013 · Cited by 169
c-Met as a Target for Personalized Therapy
Garajová, I., Giovannetti, E., Biasco, G., & Peters, G. J. (2015) · Translational Oncogenomics · doi:10.4137/tog.s30534 · Cited by 146
EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors
Bladt, F., Faden, B., Friese‐Hamim, M., Knuehl, C., Wilm, C., Fittschen, C., Grädler, U., Meyring, M., Dorsch, D., Jaehrling, F., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3247 · Cited by 140
Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers
Cortot, A. B., Kherrouche, Z., Descarpentries, C., Wislez, M., Baldacci, S., Furlan, A., & Tulasne, D. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw262 · Cited by 135
Self-citationOu, S. I., Young, L., Schrock, A. B., Johnson, A., Klempner, S. J., Zhu, V. W., Miller, V. A., & Ali, S. M. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.119 · Cited by 133
Suzawa, K., Offin, M. D., Lu, D., Kurzatkowski, C., Vojnic, M., Smith, R. S., Sabari, J. K., Tai, H., Mattar, M. S., Khodos, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1640 · Cited by 131
Rotow, J. K., Gui, P., Wu, W., Raymond, V. M., Lanman, R. B., Kaye, F. J., Peled, N., de la Cruz, F. F., Nadres, B., Corcoran, R. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1667 · Cited by 112
Jamme, P., Fernandes, M., Copin, M., Descarpentries, C., Escande, F., Morabito, A., Grégoire, V., Jamme, M., Baldacci, S., Tulasne, D., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.027 · Cited by 97
Self-citationFalchook, G. S., Kurzrock, R., Amin, H. M., Xiong, W., Fu, S., Piha-Paul, S. A., Jankú, F., Eskandari, G., Catenacci, D. V. T., Klevesath, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2860 · Cited by 95
Self-citationBahcall, M., Awad, M. M., Sholl, L. M., Wilson, F. H., Xu, M., Wang, S., Palakurthi, S. S., Choi, J., Ivanova, E. V., Leonardi, G. C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0876 · Cited by 94
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping
Salgia, R., Sattler, M., Scheele, J., Stroh, C., & Felip, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102022 · Cited by 76
Self-citationManaging Treatment–Related Adverse Events Associated with Alk Inhibitors
Rothenstein, J. M., & Letarte, N. (2014) · Current Oncology · doi:10.3747/co.21.1740 · Cited by 70
Pruis, M. A., Geurts-Giele, W. R. R., von der, T. J. H., Meijssen, I. C., Dinjens, W. N. M., Aerts, J. G. J. V., Dingemans, A. C., Lolkema, M. P., Paats, M. S., & Dubbink, H. J. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.11.010 · Cited by 62
New Era for Next-Generation Sequencing in Japan
Takeda, M., Sakai, K., Takahama, T., Fukuoka, K., Nakagawa, K., & Nishio, K. (2019) · Cancers · doi:10.3390/cancers11060742 · Cited by 29
Decaens, T., Barone, C., Assénat, E., Wermke, M., Fasolo, A., Merle, P., Blanc, J., Grando, V., Bruns, R., Sträub, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy432.004 · Cited by 8
Self-citation
Cited by
Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,576
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,392
Toward personalized treatment approaches for non-small-cell lung cancer
Wang, M., Herbst, R. S., & Boshoff, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01450-2 · Cited by 1,093
Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer
Wolf, J., Seto, T., Han, J.-Y., Reguart, N., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Hida, T., de Jonge, M., Orlov, S. V., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002787 · Cited by 1,000
Self-citationTargeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
Tan, A. C., & Tan, D. S. W. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01626 · Cited by 779
Metadata
- Authors
- Paik, P. K., Felip, E., Veillon, R., Sakai, H., Cortot, A. B., Garassino, M. C., Mazieres, J., Viteri, S., Senellart, H., Van Meerbeeck, J., Raskin, J., Reinmuth, N., Conte, P., Kowalski, D., Cho, B. C., Patel, J. D., Horn, L., Griesinger, F., Han, J.-Y., Kim, Y.-C., Chang, G.-C., Tsai, C.-L., Yang, J. C.-H., Chen, Y.-M., Smit, E. F., van der Wekken, A. J., Kato, T., Juraeva, D., Stroh, C., Bruns, R., Straub, J., Johne, A., Scheele, J., Heymach, J. V., & Le, X.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-09-03
- Volume
- 383
- Issue
- 10
- Pages
- 931-943
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3031018272
- Cited by
- 870
- References
- 38
- FWCI
- 61.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.